Mathias SD, Bussel JB, George JN, McMillan R, Okano GJ, Nichol JL. A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: its development and validation. Health Qual Life Outcomes, 2007; 5: 11.
Page L, Psaila B, Provan D, Hamilton JM, Jenkins JM, Elish AS, Lesser ML, Bussel JB. The ITP Bleeding Score (IBLS): Assessment of Bleeding in Patients with Immune Thrombocytopenic Purpura (ITP). British Journal of Haematology, 2007; 138(2): 245-8.
Berkowitz RL, Lesser ML, McFarland JG, Wissert M, Primiani A, Hung C, and Bussel JB. An antepartum treatment trial without early cordocentesis for “standard risk” alloimmune thrombocytopenia: A randomized controlled trial. Obstetrics & Gynecology, 2007; 110 (2 Pt 1): 249-55.
Herve M, Isnardi I, Ng YS, Bussel JB, Ochs HD, Cunningham-Rundles C, Meffre E. CD40 ligand and MHC class II expression are essential for human peripheral B cell tolerance. J Exp Med, 2007; 204(7): 1583-93.
Tarantino MD, Bussel JB, Cines DB, McCrae KR, Gernsheimer T, Liebman HA, Wong WY, Kulkarni R, Grabowski E, McMillan R. A closer look at intravascular hemolysis (IVH) following intravenous anti-D for immune thrombocytopenic purpura (ITP). Blood, 2007; 109(12): 5527.
Boruchov DM, Gururangan S, Driscoll MC, Bussel JB. Multi-agent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP). Blood, 2007; 110(10): 3526-31.
Zhang L, Radigan L, Salzer U, Behrens T, Grimbacher B, Diaz G, Bussel JB, and Cunningham-Rundles C. Transmembrane activator and calcium-modulating cyclophilin ligand interactor mutations in Common Variable Immunodeficiency: Clinical and Immunologic Outcomes in Heterozygotes. Journal of Allergy and Clinical Immunology, 2007; 120: 1178-85.
Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, Kloczko J, Hassani H, Mayer B, Stone NL, Arning M, Provan D, Jenkins JM.Eltrombopag, an Oral Platelet Growth Factor, for the Treatment of Patients with Chronic Idiopathic Thrombocytopenic Purpura. NEJM, 2007; 357(22): 2237-47.
Bussel JB, Tarantino MD, Nalysnyk L, Fahrbach K, Sercus B, Genereux M, and Sinclair C. Efficacy and safety of intravenous rhesus 0 human immune globulin (IV RhIG) and standard polyclonal intravenous immune globulins (IVIG) in the treatment of immune thrombocytopenic purpura: A systematic review. U.S. Hematology Touch Briefings, 2007; 3-7.
Bussel JB, Hanna K, and the IGIV-C in ITP Study Group. Safety and tolerability of a novel chromatography-based intravenous immunoglobulin when administered at a high infusion rate in patients with immune thrombocytopenic purpura (ITP). American Journal of Hematology, 2007; 82: 192-198.
Scaradavou A, Cunningham-Rundles S, Ho JL, Folman C, Doo H, and Bussel JB. Superior effect of intravenous anti-D compared to IV gammaglobulin in the treatment of HIV-thrombocytopenia: results of a small, randomized prospective comparison. American Journal of Hematology, 2007; 82(5): 335-41.
Giulino LB, Bussel JB, Neufeld EJ, and the Pediatric and Platelet Immunology Committees of the TMH clinical trial network. Treatment with Rituximab in benign and malignant hematologic disorders in children. Journal of Pediatrics, 2007; 150(4): 338-44.
McMillan R, Bussel JB, George JN, Lalla D, Nichol JL. Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. American Journal of Hematology, 2008; 83(2): 150-4.
Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, George JN, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomized controlled trial. Lancet, 2008; 371: 395-403.
Patel VL, Schwartz J, Bussel JB. The Effect of Blocking the CD40-CD40ligand Pathway in Patients with Immune Thrombocytopenic Purpura. British Jounral of Haem, 2008; 141: 545-48.
Mathias SD, Gao SK, Miller KL, Cella D, Snyder C, Turner R, Wu A, Bussel JB, George JN, McMIllan R, Wysocki DK, Nichol JN. Impact of chronic immune thrombocytopenic purpura (ITP) on health-related quality of life: a conceptual model starting with the patient perspective. Health and Quality of Life Outcomes, 2008; 6:13.
Yu J, Heck S, Patel V, Levan J, Yu Y, Bussel JB, Yazdanbakhsh K. Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood, 2008; 112(4): 1325-28.
Wasserstrom H, Bussel JB, Lim LCL, Cunningham-Rundles C. Memory B cells and Antibody to Pneumococcal Vaccine in Splenectomized Subjects. J Immuno, 2008; 181(5): 3684-9.
Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, Godeau B, Lechner K, Mazzucconi MG, McMillan R, Sanz MA, Imbach P, Blanchette V, Kuhne T, Ruggeri M, George JN. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura (ITP) of adults and children: report from an international working group. Blood, 2009; 113(11): 2386-93.
Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, Salama A, Jenkins JM, Roychowdhury Db, Mayer B, Stone N, Arning M. Eltrombopag Increases Platelet Counts and Reduces Bleeding During Treatment of Chronic Idiopathic Thrombocytopenic Purpura (ITP): A Randomized, Double Blind, Placebo-controlled Study. Lancet, 2009; 373(9664): 641-8.
Podolanczuk A, Lazarus AH, Crow AR, Grossbard E, Bussel JB. Of Mice and Men: an Open Label Pilot Study for Treatment of Immune Thrombocytopenic Purpura (ITP) by an Inhibitor of Syk. Blood, 2009; 113(14): 3154-60.
Bussel JB, Kuter D, Pullarkat VA, Lyons R, Guo M, Nichol J. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood, 2009; 113(10): 2161-71.
Stasi R, Sarpatwari A, Segal JB, Osborn J, Evangelista ML, Cooper N, Provan D, Newland A, Amadori S, Bussel JB. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura. A systematic review. Blood, 2009; 113(6): 1231-40.
Mueller BU, Bennett CM, Feldman HA, Bussel JB, Abshire TC, Moore TB, Sawaf H, Loh ML, Rogers ZR, Glader BE, McCarthy MC, Mahoney DH, Olson TA, Feig SA, Lorenzana AN, Mentzer WC, Buchanan GR, Neufeld EJ; for the Pediatric Rituximab/ITP Study Group, the Glaser Pediatric Research Network. One year follow-up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab. Pediatric Blood & Cancer, 2009; 52(2): 259-62.
DiMaggio D, Anderson A, Bussel JB. Cytomegalovirus Causes Refractory Immune Thrombocytopenic Purpura. British Journal of Haematology, 2009; 146(1): 104-12.
Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP Syndrome: a diverse set of disorders with different immune mechanisms. Blood, 2009; 113(26): 6511-21.
Sharma G, Nesin M, Feuerstein M, Bussel JB. Maternal and Neonatal Characteristics Associated with Neonatal Neutropenia in Hypertensive Pregnancies. American Journal of Perinatology, 2009; in press.
Hasan A, Michel M, Patel V, Stasi R, Cunningham Rundles S, Leonard J, Bussel JB. Repeated courses of rituximab in chronic ITP: three different regimens. Am J Heme, 2009; in press.
Education
B.S.,
Yale University,
1971
M.D.,
Columbia University College of Physicians and Surgeons,
1975
Appointments
Professor of Pediatrics Weill Cornell Medical College
